| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-12-18 |
| タイトル |
|
|
タイトル |
Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
tirzepatide |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
dulaglutide |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
hemodialysis |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
continuous glucose monitoring |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
GLP-1 |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
GIP |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
CGM |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
glycemic control |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Otsuka, Emiko
Kitamura, Mineaki
Funakoshi, Satoshi
Mukae, Hiroshi
Nishino, Tomoya
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Tirzepatide—a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist—is used to treat type 2 diabetes. However, the efficacy and safety of tirzepatide in patients undergoing hemodialysis remain unclear. Methods: We conducted a single-center retrospective study of patients with type 2 diabetes undergoing hemodialysis who were transitioned from dulaglutide to tirzepatide. We continuously monitored glucose levels in patients undergoing hemodialysis before and after switching from dulaglutide to tirzepatide. Results: Fourteen patients (mean age: 61.9 ± 9.9 years, male: female = 11:3) were included in this study. After switching to tirzepatide, time in range increased to 50.8% from 42.7% (p = 0.02), time above range decreased to 37.8% from 48.4% (p = 0.02), and mean glucose levels decreased to 137.4 mg/dL from 156.6 mg/dL (p = 0.006). In contrast, there was no significant difference in time below range before and after tirzepatide administration (11.3% and 8.9%) (p = 0.75). Three patients experienced dyspepsia (21.4%), and one patient experienced nausea (7.1%); however, no critical adverse events were reported. Conclusion: Transitioning from dulaglutide to tirzepatide improved glycemic control without increasing hypoglycemia in patients undergoing hemodialysis for type 2 diabetes. |
|
言語 |
en |
| 書誌情報 |
en : Frontiers in Pharmacology
巻 15,
p. art. no. 1362242,
発行日 2024-05-30
|
| 出版者 |
|
|
出版者 |
Frontiers Media SA |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1663-9812 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.3389/fphar.2024.1362242 |
| 権利 |
|
|
権利情報 |
© 2024 Otsuka, Kitamura, Funakoshi, Mukae and Nishino. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Frontiers in Pharmacology, 15, art. no. 1362242; 2024 |
|
言語 |
en |
FP15_1362242.pdf (1.2 MB)
